PRESS RELEASE
With a capital increase, the CytoTools AG creates the conditions for the realisation
of the medical product strategy


Gross issue proceeds amounting to 1.4 million EUR
Positive feedback from the market for DermaPro® as a medical product
Darmstadt, 21st April 2017 – The CytoTools AG, a technology holding with interests in the
pharmaceutical and medical products fields, has placed a capital increase, under partial
utilisation of the approved capital, with the exclusion of subscription rights. The 100,000
newly created shares were subscribed by institutional investors at an issue price of 14.00
EUR each. With the new financial means, the company is creating the basis for extending
the strategy into the medical products segment. Also, this increase in capital means that
the CytoTools AG has further strengthened its financial basis. It now has a liquidity of
about 2.7 million euros at its disposal and, as in the past, does not make use of external
capital.
The issue proceeds, as well as further accompanying capitalisation measures in the
subsidiary company DermaTools Biotech GmbH, shall be used to extend the potential of
the wound healing active substance DermaPro® to medical products, and thus open up a
further market for the company. In this way, DermaTools makes a further step towards its
strategic target - being able to offer a comprehensive and overarching wound management
system for important chronic dermatological problems.
Within the scope of discussions with medical product manufacturers, among these large
wound dressing producers, the CytoTools AG received very positives feedback to
DermaPro® as a medical product. Now, using the means from the cash capital increase,
the company will immediately begin the work on a possible CE certification. With the
approval of a national regulatory authority, the certification process could already be
completed next year.
The financing of the planned new clinical phase III trial should be completed by the
placement of the convertible bond. The subscription period here lasts until 5th May 2017.
Furthermore, within the framework of the authorised capital, the company has the
possibility of issuing further shares, with the exclusion of subscription rights. For this, a
new placement price will be determined depending on the market circumstances.
PRESS RELEASE
This press release contains specific future oriented statements. These reflect the opinion of CytoTools on the
date of this release. The actual results achieved by CytoTools could substantially deviate from the futureoriented statements made. CytoTools is not obligated to update these future-oriented statements.
About CytoTools
CytoTools AG is a German biotechnology company focused on translating fundamental biology
research on the mechanisms of cell growth and programmed cell death into unique therapies that
are designed to treat the cause of the disease rather than the symptoms. The Company has
developed a robust and diverse pipeline of disease modifying therapies that comprise proprietary
small molecules and biologics. These have the potential to provide new treatment options in
dermatology, cardiology and angiology, urology and oncology. CytoTools AG is structured as an
investment and holding company and as such holds investments in its subsidiaries DermaTools
Biotech GmbH (57%) and CytoPharma GmbH (42%).
Contact:
CytoTools AG
Dr. Mark-André Freyberg
Klappacher Str. 126
D-64285 Darmstadt
Tel.: +49-6151-95158-12
Fax: +49-6151-95158-13
E-Mail: [email protected]